Oncogene-dependent control of miRNA biogenesis and metastatic progression in a model of undifferentiated pleomorphic sarcoma

Journal of Pathology

Volumn 229, Issue 1, 2013, Pages 132-140

  Mito, Jeffrey K ^a   Min, Hooney D ^a   Ma, Yan ^a   Carter, Jessica E ^a   Brigman, Brian E ^a   Dodd, Leslie ^a   Dankort, David ^b   McMahon, Martin ^c   Kirsch, David G ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

metastasis; miRNA biogenesis; mouse models; soft tissue sarcoma; undifferentiated pleomorphic sarcoma

Indexed keywords

DICER; MICRORNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOGENESIS; CANCER GROWTH; CONTROLLED STUDY; DISTANT METASTASIS; GENE CONTROL; GENE MUTATION; HAPLOINSUFFICIENCY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; TUMOR GROWTH; UNDIFFERENTIATED PLEOMORPHIC SARCOMA;

ANIMALS; CELL DIFFERENTIATION; DEAD-BOX RNA HELICASES; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HAPLOINSUFFICIENCY; MAP KINASE SIGNALING SYSTEM; MICE; MICRORNAS; MUTATION; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS); RIBONUCLEASE III; SARCOMA; SOFT TISSUE NEOPLASMS; TIME FACTORS;

EID: 84872865307     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4099     Document Type: Article

References (40)

1. Coindre JM, Terrier P, Guillou L, et al,. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer 2001; 91: 1914-1926.
2. Zagars GK, Ballo MT, Pisters PW, et al,. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 2003; 97: 2530-2543.
3. Kirsch DG, Dinulescu DM, Miller JB, et al,. A spatially and temporally restricted mouse model of soft tissue sarcoma. Nature Med 2007; 13: 992-997.
4. Mito JK, Riedel RF, Dodd L, et al,. Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS One 2009; 4: e8075.
5. Nicoloso M, Spizzo R, Shimizu M, et al,. MicroRNAs-the micro steering wheel of tumour metastases. Nature Rev Cancer 2009; 9: 293-302.
6. Lee Y, Kim M, Han J, et al,. MicroRNA genes are transcribed by RNA polymerase II. EMBO J 2004; 23: 4051-4060.
7. Gregory RI, Yan KP, Amuthan G, et al,. The Microprocessor complex mediates the genesis of microRNAs. Nature 2004; 432: 235-240.
8. Lee Y, Jeon K, Lee JT, et al,. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 2002; 21: 4663-4670.
9. Chendrimada TP, Gregory RI, Kumaraswamy E, et al,. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. Nature 2005; 436: 740-744.
10. Bartel DP,. MicroRNAs: target recognition and regulatory functions. Cell 2009; 136: 215-233.
11. Lu J, Getz G, Miska EA, et al,. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-838.
12. Wong CM, Wong CC, Lee JM, et al,. Sequential alterations of miRNA expression in hepatocellular carcinoma development and venous metastasis. Hepatology 2012; 55: 1453-1461.
13. Heinzelmann J, Henning B, Sanjmyatav J, et al,. Specific miRNA signatures are associated with metastasis and poor prognosis in clear cell renal cell carcinoma. World J Urol 2011; 29: 367-373.
14. van Kouwenhove M, Kedde M, Agami R,. MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nature Rev Cancer 2011; 11: 644-656.
15. Dehner LP, Jarzembowski JA, Hill DA,. Embryonal rhabdomyosarcoma of the uterine cervix: a report of 14 cases and a discussion of its unusual clinicopathological associations. Mod Pathol 2012; 25: 602-614.
16. Heravi-Moussavi A, Anglesio MS, Cheng SW, et al,. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med 2012; 366: 234-242.
17. Foulkes W, Bahubeshi A, Hamel N, et al,. Extending the phenotypes associated with DICER1 mutations. Hum Mutat 2011; 32: 1381-1385.
18. Kumar MS, Pester RE, Chen CY, et al,. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev 2009; 23: 2700-2704.
19. Merritt WM, Lin YG, Han LY, et al,. Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 2008; 359: 2641-2650.
20. Lin RJ, Lin YC, Chen J, et al,. microRNA signature and expression of Dicer and Drosha can predict prognosis and delineate risk groups in neuroblastoma. Cancer Res 2010; 70: 7841-7850.
21. Faber C, Horst D, Hlubek F, et al,. Overexpression of Dicer predicts poor survival in colorectal cancer. Eur J Cancer 2011; 47: 1414-1419.
22. Chiosea S, Jelezcova E, Chandran U, et al,. Up-regulation of dicer, a component of the microRNA machinery, in prostate adenocarcinoma. Am J Pathol 2006; 169: 1812-1820.
23. Paroo Z, Ye X, Chen S, et al,. Phosphorylation of the human microRNA-generating complex mediates MAPK/Erk signaling. Cell 2009; 139: 112-122.
24. Davies H, Bignell GR, Cox C, et al,. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954.
25. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D,. RAS oncogenes: weaving a tumorigenic web. Nature Rev Cancer 2011; 11: 761-774.
26. Sharma SV, Bell DW, Settleman J, et al,. Epidermal growth factor receptor mutations in lung cancer. Nature Rev Cancer 2007; 7: 169-181.
27. Jackson EL, Willis N, Mercer K, et al,. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 2001; 15: 3243-3248.
28. Jonkers J, Meuwissen R, van der Gulden H, et al,. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nature Genet 2001; 29: 418-425.
29. Dankort D, Filenova E, Collado M, et al,. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007; 21: 379-384.
30. Harfe BD, McManus MT, Mansfield JH, et al,. The RNaseIII enzyme Dicer is required for morphogenesis but not patterning of the vertebrate limb. Proc Natl Acad Sci U S A 2005; 102: 10898-10903.
31. Mito JK, Ferrer JM, Brigman BE, et al,. Intraoperative detection and removal of microscopic residual sarcoma using wide-field imaging. Cancer 2012; DOI: 10.1002/cncr.27458. PMID: 22437667.
32. Pratilas CA, Taylor BS, Ye Q, et al,. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009; 106: 4519-4524.
33. V600E. Cancer Res 2012; 72: 3048-3059.
34. Kumar MS, Lu J, Mercer KL, et al,. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nature Genet 2007; 39: 673-677.
35. Drobnjak M, Latres E, Pollack D, et al,. Prognostic implications of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft-tissue sarcomas. J Natl Cancer Inst 1994; 86: 549-554.
36. Singer S, Corson JM, Gonin R, et al,. Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma. Ann Surg 1994; 219: 165-173.
37. Esteller M,. Non-coding RNAs in human disease. Nature Rev Genet 2011; 12: 861-874.
38. Meng S, Zhang M, Pan W, et al,. Tyrosines 303/343/353 within the Sprouty-related domain of Spred2 are essential for its interaction with p85 and inhibitory effect on Ras/ERK activation. Int J Biochem Cell Biol 2012; 44: 748-758.
39. Fong CW, Chua MS, McKie AB, et al,. Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res 2006; 66: 2048-2058.
40. Suzuki H, Yamagata K, Sugimoto K, et al,. Modulation of microRNA processing by p53. Nature 2009; 460: 529-562.